Publication Date
2018
Journal Title
World J Oncol
Abstract
Treatment of lung cancer has been revolutionized with development of drugs that target key driver mutations and immune checkpoints. Until recently, it was believed that these driver mutations are mutually exclusive. However, few reports have emerged citing the presence of both mutations either synchronously or metachronously. We describe a case report of lung adenocarcinoma harboring two driver mutations in the same tumor cells as well as exhibiting high PDL1 expression. We further discuss the possible association of these driver mutations with PDL1 expression.
Volume Number
9
Issue Number
2
Pages
50 - 55
Document Type
Article
Status
Faculty; Northwell Researcher; Northwell Resident
Facility
School of Medicine; Northwell Health
Primary Department
Hematology/Medical Oncology
PMID
DOI
10.14740/wjon1090e